We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
Cap. Flow
+$191M
Cap. Flow %
13.26%
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55

Top Buys

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$24.7M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.4M
4
STJ
St Jude Medical
STJ
+$16.6M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$41.5M
2
HUM icon
Humana
HUM
+$20.1M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.4M
4
BAX icon
Baxter International
BAX
+$9.04M
5
XLRN
Acceleron Pharma
XLRN
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.68%
2 Consumer Staples 0.52%
3 Consumer Discretionary 0.08%
4 Financials 0.04%
5 Industrials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNCA
151
DELISTED
Genocea Biosciences, Inc.
GNCA
$71K ﹤0.01%
2,164
-62,413
-97% -$2.29M
AIMT
152
DELISTED
Aimmune Therapeutics
AIMT
$70K ﹤0.01%
+6,448
New +$87.6K
CORT icon
153
Corcept Therapeutics
CORT
$13.3B
$60K ﹤0.01%
+11,000
New +$57.2K
AVXS
154
DELISTED
AveXis, Inc. Common Stock
AVXS
$58K ﹤0.01%
1,515
-148,485
-99% -$5.02M
ATRA icon
155
Atara Biotherapeutics
ATRA
$97.5M
$56K ﹤0.01%
+100
New +$48K
MCRB icon
156
Seres Therapeutics
MCRB
$48.4M
$45K ﹤0.01%
+77
New +$45.2K
JUNO
157
DELISTED
Juno Therapeutics, Inc.
JUNO
$43K ﹤0.01%
+1,113
New +$46.2K
DVAX
158
DELISTED
Dynavax Technologies
DVAX
$36K ﹤0.01%
+2,499
New +$42.7K
LCTX icon
159
Lineage Cell Therapeutics
LCTX
$281M
$36K ﹤0.01%
+15,705
New +$38.5K
CAPR icon
160
Capricor Therapeutics
CAPR
$533M
$16K ﹤0.01%
400
– –
AVGR
161
DELISTED
Avinger, Inc. Common Stock
AVGR
– –
0
– –
GKOS icon
162
Glaukos
GKOS
$10.7B
$9K ﹤0.01%
+300
New +$6.94K
VYGR icon
163
Voyager Therapeutics
VYGR
$214M
$7K ﹤0.01%
+650
New +$7.95K
INGN icon
164
Inogen
INGN
$148M
$6K ﹤0.01%
125
– –
TCRT icon
165
Alaunos Therapeutics
TCRT
$4.5M
$5K ﹤0.01%
+7
New +$7.62K
DCOY
166
Decoy Therapeutics
DCOY
$1.99M
– –
0
– –
TNGN
167
DELISTED
TENGION INC COM NEW STK (DE)
TNGN
$1K ﹤0.01%
+1,826,399
New +$1K
ACAD icon
168
PUT
Acadia Pharmaceuticals
ACAD
$5.12B
– –
-200,000
Closed -$2.8M
ADVM
169
DELISTED
Adverum Biotechnologies
ADVM
– –
-2,000
Closed -$103K
AMED
170
DELISTED
Amedisys
AMED
– –
-10,493
Closed -$507K
AMGN icon
171
Amgen
AMGN
$239B
– –
-30,000
Closed -$4.5M
APYX icon
172
Apyx Medical
APYX
$129M
– –
-162,700
Closed -$272K
ARMP icon
173
Armata Pharmaceuticals
ARMP
$201M
– –
-571
Closed -$315K
BAX icon
174
CALL
Baxter International
BAX
$13.8B
– –
-175,400
Closed -$7.17M
BAX icon
175
Baxter International
BAX
$13.8B
– –
-220,000
Closed -$9.04M
5 6
7
8 9

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors deployed $191M of net new capital in Q2 2016, opening 57 new positions and adding to 37 existing holdings. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Five Prime Therapeutics, Inc., an estimated $12.4M trimmed.

  • Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
  • Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
  • Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
  • Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
  • Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
  • Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.